Ghost Tree Capital, LLC Mersana Therapeutics, Inc. Transaction History

Ghost Tree Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $188,650 - $584,937	61,250 New	61,250 $201,000
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $3.85 Million - $6.51 Million	-450,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $2.3 Million - $3.98 Million	-150,000 Reduced 25.0%	450,000 $7.28 Million
Q4 2020 Feb 16, 2021	SELL	$16.84 - $27.59 $7.58 Million - $12.4 Million	-450,000 Reduced 42.86%	600,000 $16 Million
Q3 2020 Nov 16, 2020	BUY	$16.2 - $25.7 $6.89 Million - $10.9 Million	425,000 Added 68.0%	1,050,000 $19.6 Million
Q2 2020 Aug 14, 2020	SELL	$5.24 - $23.4 $7.21 Million - $32.2 Million	-1,375,000 Reduced 68.75%	625,000 $14.6 Million
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $5.29 Million - $11.1 Million	1,200,000 Added 150.0%	2,000,000 $11.7 Million
Q4 2019 Feb 14, 2020	BUY	$1.45 - $6.73 $1.16 Million - $5.38 Million	800,000 New	800,000 $4.58 Million
Q3 2018 Nov 14, 2018	SELL	$10.0 - $19.02 $6 Million - $11.4 Million	-600,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$14.2 - $22.68 $4.57 Million - $7.3 Million	321,756 Added 115.64%	600,000 $10.7 Million
Q1 2018 May 15, 2018	BUY	$13.56 - $18.48 $3.77 Million - $5.14 Million	278,244 New	278,244 $4.39 Million

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $59.3M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.